Groundbreaking Therapy Reverses Incurable Blood Cancer in Select Patients

A groundbreaking treatment that once seemed like a concept from science fiction has successfully reversed severe and previously untreatable blood cancers in a number of patients, according to medical professionals.

This innovative therapy utilizes targeted DNA editing of white blood cells, transforming them into a potent “living drug” capable of combating cancer.

The first patient to undergo this treatment, a girl whose journey was documented in 2022, remains cancer-free and aspires to pursue a career in cancer research.

Recent Successes in Treatment

In addition to her, eight other children and two adults diagnosed with T-cell acute lymphoblastic leukemia have received the same therapy, resulting in approximately 64% of these patients entering remission.

T-cells, the body’s natural defenders, typically identify and eliminate threats. However, in cases of this type of leukemia, they multiply uncontrollably.

For the participants in this trial, traditional treatments like chemotherapy and bone marrow transplants had failed, leaving only palliative care options to ease their suffering.

“I genuinely believed I wouldn’t survive and that I would miss out on all the experiences every child should have,” shared 16-year-old Alyssa Tapley from Leicester.

Alyssa was the first individual worldwide to receive this treatment at Great Ormond Street Hospital and is now thriving.

The revolutionary procedure, administered three years ago, involved eradicating her existing immune system and developing a new one. During her four-month hospital stay, she could not see her brother due to infection risks.

Today, her cancer is undetectable and she only requires annual follow-ups. Alyssa is currently engaged in A-level studies, participating in the Duke of Edinburgh Award, contemplating driving lessons, and planning her future.

“I’m exploring an apprenticeship in biomedical science, and I hope to eventually contribute to blood cancer research,” she stated.

How the Therapy Works

The team from University College London and Great Ormond Street Hospital employed a technique known as base editing.

DNA is constructed from four fundamental building blocks: adenine (A), cytosine (C), guanine (G), and thymine (T). Just as letters form words in a language, these bases assemble the genetic blueprint for living organisms.

Base editing enables scientists to precisely target and modify a specific base within the genetic sequence, effectively rewriting the instructions encoded within DNA.

The researchers aimed to leverage the innate capabilities of healthy T-cells to identify and eradicate threats, using this mechanism against T-cell acute lymphoblastic leukemia.

This process is complex, requiring the engineers to modify the T-cells so they can target malignant cells without harming themselves.

Steps in Genetic Modification

The initial step involved disabling the T-cells’ natural targeting function to prevent them from attacking the patient’s body.

The next modification eliminated a chemical marker, CD7, found on all T-cells. This removal was crucial to ensure the therapy would not self-destruct.

The third alteration provided the T-cells with an “invisibility cloak” to shield them from being destroyed by chemotherapy drugs.

Finally, the T-cells were programmed to seek out any cell displaying the CD7 marker.

Although the engineered T-cells would destroy every other T-cell they encountered, both malignant and healthy, they were designed to avoid attacking one another.

The treatment is infused into the patients, and if cancer remains undetectable after four weeks, a bone marrow transplant is performed to regenerate their immune system.

“A few years back, this would have seemed like a fantasy,” remarked Professor Waseem Qasim from UCL and Great Ormond Street.

“We essentially have to dismantle the entire immune system. It’s a profound and intensive treatment that places significant demands on patients, but when it proves effective, the results are remarkable.”

Study Findings and Implications

The findings, published in a prominent medical journal, detail the outcomes for the first 11 patients treated at Great Ormond Street and King’s College Hospital. Among them, nine reached a deep remission that allowed for a bone marrow transplant.

Seven of these patients remain free of disease between three months to three years post-treatment.

Among the notable risks associated with this treatment is the potential for infections during the period when the immune system is compromised.

In two instances, the leukemia managed to shed its CD7 markers, enabling it to evade detection and re-emerge within the body.

“Considering the aggressive nature of this leukemia, these results are quite remarkable, and I am thrilled that we can offer hope to patients who had seemingly none,” stated Dr. Robert Chiesa from the bone marrow transplant unit at Great Ormond Street Hospital.

Dr. Deborah Yallop, a consultant hematologist at King’s, emphasized, “We have observed significant responses in eliminating leukemia that previously appeared untreatable – this is an exceptionally powerful approach.”

Commenting on the research, Dr. Tania Dexter, a senior medical officer with a UK stem cell charity, noted, “Given these patients had minimal chances of survival prior to the trial, these results provide hope that such innovative treatments will continue to evolve and become accessible to a broader range of patients.”

Stay informed with our flagship newsletter, delivering all the top headlines to kickstart your day. Sign up here.